Ben Glickman
Reporter, The Wall Street Journal Ben Glickman is a reporter on the Real-Time desk, where he writes about corporate breaking news. He started at The Wall Street Journal in New York as a member of the summer 2023 newsroom intern class. Ben is a recent graduate of Brown University, where he studied political science and data science. He previously interned at the Financial Times and served as editor in chief of his college newspaper, the Brown Daily Herald. He also has written for various local newspapers, including on Cape Cod and in Pelham, N.Y. Latest Articles Business
33%
The Daily's Verdict
This author has a poor reputation for journalistic standards and is not considered a reliable news source.
Bias
50%
Examples:
- citing weaker demand for its electrified rentals.
- , Hertz said it would sell about 20,000 of its global electric vehicle fleet
- implying that the EV market is saturated when in reality there may not have been any significant change.
Conflicts of Interest
15%
Examples:
- None
Contradictions
15%
Examples:
- The statement 'Hertz is selling about a third of its global electric vehicle fleet' is misleading as it implies Hertz has a significant number of EVs and therefore sells them frequently, when in reality they may only have sold 20,000 EVs worldwide which is not a third of their global fleet.
- The statement 'weaker demand for electrified rentals' is misleading as it implies there has been a decline in demand for EVs when in reality there may not have been any significant change.
Deceptions
20%
Examples:
- , Ben Glickman January 11, 2024 Business
- Bloomberg News Contributor
- élise Beasley
- The article is straightforward and factual, with no apparent deception.
- The Wall Street Journal
Recent Articles
Hertz to Sell 20,000 Electric Vehicles in U.S., Expects $35 Million in Incremental Free Cash Flow by 2024 and 2025
Broke On: Thursday, 11 January 2024Hertz Global Holdings plans to sell around 20,000 electric vehicles from its U.S. fleet in order to balance better the expected demand and supply of EVs, which is estimated to generate $250 million to $300 million in incremental free cash flow by 21-24 and 25. AbbVie Acquires Neuroscience Drugmaker Cerevel Therapeutics for $8.7 Billion
Broke On: Wednesday, 06 December 2023AbbVie has acquired Cerevel Therapeutics for $8.7 billion. This is AbbVie's second billion-dollar acquisition in less than a week, following its purchase of Immunogen for $10 billion. Cerevel brings with it drugs such as Emraclidine, an experimental treatment for schizophrenia and Alzheimer's disease psychosis. The deal values Cerevel Therapeutics at $45 per share.